Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1367, Issue 1, 2016, Pages 12-20

  Cunnane, Stephen C ^a   Courchesne Loyer, Alexandre ^a   St Pierre, Valérie ^a   Vandenberghe, Camille ^a   Pierotti, Tyler ^a,b   Fortier, Mélanie ^a   Croteau, Etienne ^a   Castellano, Christian Alexandre ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b BISHOP'S UNIVERSITY   (Canada)

Author keywords

Acetoacetate (AcAc); Alzheimer's disease; Beta hydroxybutyrate ( HB); Glucose; Ketones; Medium chain triglycerides (MCT)

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; DECANOIC ACID; GLUCOSE; KETONE; MEDIUM CHAIN TRIACYLGLYCEROL; OCTANOIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE DISEASE; AGING; ALZHEIMER DISEASE; ARTICLE; CHRONIC DISEASE; COGNITIVE DEFECT; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERKETONEMIA; KETOACIDOSIS; KETOGENESIS; KETOGENIC DIET; MILD COGNITIVE IMPAIRMENT; ANIMAL; BRAIN; ENERGY METABOLISM; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; ENERGY METABOLISM; GLUCOSE; HUMANS; KETOGENIC DIET; KETONES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84954271182     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12999     Document Type: Article

References (70)

1. Cunnane, S. et al. 2011. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27: 3-20.
2. Terry, R.D. et al. 1991. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30: 572-580.
3. Musa-Veloso, K. et al. 2006. Breath acetone predicts plasma ketone bodies in children with epilepsy on a ketogenic diet. Nutrition 22: 1-8.
4. Hertz, L., Y. Chen & H.S. Waagepetersen . 2015. Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, beta-amyloid toxicity, and astrocyte function. J. Neurochem. 134: 7-20.
5. VanItallie, T.B. 2015. Biomarkers, ketone bodies, and the prevention of Alzheimer's disease. Metabolism 64: S51-S57.
6. Scholl, M. et al. 2011. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. J. Alzheimers Dis. 24: 495-506.
7. Fox, N.C. et al. 1997. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 120(Pt 3): 491-501.
8. Blennow, K., M.J. de Leon & H. Zetterberg . 2006. Alzheimer's disease. Lancet 368: 387-403.
9. Kennedy, A.M. et al. 1995. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186: 17-20.
10. Mosconi, L. et al. 2005. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64: 1860-1867.
11. Reiman, E.M. et al. 2004. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U.S.A. 101: 284-289.
12. Bu, G. 2009. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10: 333-344.
13. Castellano, C.A. et al. 2015. Regional brain glucose hypometabolism in young women with polycystic ovary syndrome: possible link to mild insulin resistance. PLoS One 10: e0144116.
14. Velliquette, R.A., T. O'Connor & R. Vassar . 2005. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J. Neurosci. 25: 10874-10883.
15. Nugent, S. et al. 2014. Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol. Aging 35: 1386-1395.
16. Nugent, S. et al. 2014. Glucose hypometabolism is highly localized but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. Am. J. Physiol. Endocrinol. Metab. 306: E1315-E1321.
17. Nugent, S. et al. 2015. Relationship of metabolic and endocrine parameters to brain glucose metabolism in older adults: do cognitively-normal older adults have a particular metabolic phenotype? Biogerontology. DOI 10.1007/s10522-015-9595-7.
18. Kalpouzos, G. et al. 2009. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol. Aging 30: 112-124.
19. Gibson, R.E. et al. 2000. Non-invasive radiotracer imaging as a tool for drug development. Curr. Pharm. Des. 6: 973-989.
20. Veech, R.L. et al. 2001. Ketone bodies, potential therapeutic uses. IUBMB Life 51: 241-247.
21. Blass, J.P. 2008. A new approach to treating Alzheimer's disease. Ann. N.Y. Acad. Sci. 1147: 122-128.
22. Owen, O.E. et al. 1967. Brain metabolism during fasting. J. Clin. Invest. 46: 1589-1595.
23. Drenick, E.J. et al. 1972. Resistance to symptomatic insulin reactions after fasting. J. Clin. Invest. 51: 2757-2762.
24. Flatt, J.P. 1972. On the maximal possible rate of ketogenesis. Diabetes 21: 50-53.
25. Reichard, G.A., Jr. et al. 1974. Ketone-body production and oxidation in fasting obese humans. J. Clin. Invest. 53: 508-515.
26. Garber, A.J. et al. 1974. Hepatic ketogenesis and gluconeogenesis in humans. J. Clin. Invest. 54: 981-989.
27. Hashim, S.A., A. Arteaga & T.B. Van Itallie . 1960. Effect of a saturated medium-chain triglyceride on serum-lipids in man. Lancet 1: 1105-1108.
28. Craft, S. 2009. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 66: 300-305.
29. Baker, L.D. et al. 2011. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68: 51-57.
30. Fukao, T., G.D. Lopaschuk & G.A. Mitchell . 2004. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot. Essent. Fatty Acids 70: 243-251.
31. Henderson, S.T. 2008. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 5: 470-480.
32. Mamelak, M. 2012. Sporadic Alzheimer's disease: the starving brain. J. Alzheimers Dis. 31: 459-474.
33. 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. J. Alzheimers Dis. 43: 1343-1353.
34. Ogawa, M. et al. 1996. Altered energy metabolism in Alzheimer's disease. J. Neurol. Sci. 139: 78-82.
35. Lying-Tunell, U. et al. 1981. Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol. Scand. 63: 337-350.
36. Blomqvist, G. et al. 1995. Use of R-beta-[1-11C]hydroxybutyrate in PET studies of regional cerebral uptake of ketone bodies in humans. Am. J. Physiol. 269: E948-E959.
37. Roy, M. et al. 2015. Rapid adaptation of rat brain and liver metabolism to a ketogenic diet: an integrated study using (1)H- and (13)C-NMR spectroscopy. J. Cereb. Blood Flow Metab. 35: 1154-1162.
38. Hoyer, S., K. Oesterreich & O. Wagner . 1988. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J. Neurol. 235: 143-148.
39. Cunnane, S.C. & M.A. Crawford . 2014. Energetic and nutritional constraints on infant brain development: implications for brain expansion during human evolution. J. Hum. Evol. 77: 88-98.
40. Freemantle, E. et al. 2009. Metabolic response to a ketogenic breakfast in the healthy elderly. J. Nutr. Health Aging 13: 293-298.
41. London, E.D. et al. 1986. Effects of fasting on ketone body concentrations in healthy men of different ages. J. Gerontol. 41: 599-604.
42. Page, K.A. et al. 2009. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 58: 1237-1244.
43. Krikorian, R. et al. 2012. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol. Aging 33: 425.e19-27.
44. Amiel, S.A. et al. 1991. Ketone infusion lowers hormonal responses to hypoglycaemia: evidence for acute cerebral utilization of a non-glucose fuel. Clin. Sci. (Lond.) 81: 189-194.
45. Veneman, T. et al. 1994. Effect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humans. Diabetes 43: 1311-1317.
46. Reger, M.A. et al. 2004. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging 25: 311-314.
47. Henderson, S.T. et al. 2009. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond.) 6: 31.
48. Plecko, B. et al. 2002. Oral beta-hydroxybutyrate supplementation in two patients with hyperinsulinemic hypoglycemia: monitoring of beta-hydroxybutyrate levels in blood and cerebrospinal fluid, and in the brain by in vivo magnetic resonance spectroscopy. Pediatr. Res. 52: 301-306.
49. Hasselbalch, S.G. et al. 1996. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. Am. J. Physiol. 270: E746-E751.
50. Clarke, K. et al. 2012. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 63: 401-408.
51. Newport, M.T. et al. 2015. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. Alzheimers Dement. 11: 99-103.
52. Bach, A.C. & V.K. Babayan . 1982. Medium-chain triglycerides: an update. Am. J. Clin. Nutr. 36: 950-962.
53. Traul, K.A. et al. 2000. Review of the toxicologic properties of medium-chain triglycerides. Food Chem. Toxicol. 38: 79-98.
54. Courchesne-Loyer, A. et al. 2013. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition 29: 635-640.
55. Jiang, P., W. Du & M. Wu . 2014. Regulation of the pentose phosphate pathway in cancer. Protein Cell 5: 592-602.
56. Bolanos, J.P. & A. Almeida . 2010. The pentose-phosphate pathway in neuronal survival against nitrosative stress. IUBMB Life 62: 14-18.
57. Rowe, J.W. et al. 1983. Characterization of the insulin resistance of aging. J. Clin. Invest. 71: 1581-1587.
58. Stout, R.W. 1994. Glucose tolerance and ageing. J. R. Soc. Med. 87: 608-609.
59. Bough, K.J. et al. 2006. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol. 60: 223-235.
60. 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 23: 5928-5935.
61. Kuge, Y. et al. 1995. Brain uptake and metabolism of [1-11C]octanoate in rats: pharmacokinetic basis for its application as a radiopharmaceutical for studying brain fatty acid metabolism. Ann. Nucl. Med. 9: 137-142.
62. Auestad, N. et al. 1991. Fatty acid oxidation and ketogenesis by astrocytes in primary culture. J. Neurochem. 56: 1376-1386.
63. Mochel, F. et al. 2005. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol. Genet. Metab. 84: 305-312.
64. Brunengraber, H. & C.R. Roe . 2006. Anaplerotic molecules: current and future. J. Inherit. Metab. Dis. 29: 327-331.
65. Vaishnavi, S.N. et al. 2010. Regional aerobic glycolysis in the human brain. Proc. Natl. Acad. Sci. U.S.A. 107: 17757-17762.
66. Dienel, G.A. 2012. Brain lactate metabolism: the discoveries and the controversies. J. Cereb. Blood Flow Metab. 32: 1107-1138.
67. Hyder, F. et al. 2013. Glutamatergic function in the resting awake human brain is supported by uniformly high oxidative energy. J. Cereb. Blood Flow Metab. 33: 339-347.
68. Blomqvist, G. et al. 2002. Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. Am. J. Physiol. Endocrinol. Metab. 283: E20-E28.
69. Seaton, T.B. et al. 1986. Thermic effect of medium-chain and long-chain triglycerides in man. Am. J. Clin. Nutr. 44: 630-634.
70. Pi-Sunyer, F.X., S.A. Hashim & T.B. Van Itallie . 1969. Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man. Diabetes 18: 96-100.